Associations Between Disease Activity/Severity and Damage and Health-Related Quality of Life in Adult Patients with Localized Scleroderma-A Comparison of LoSCAT and Visual Analogue Scales

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Mar 15

PMID 32168819

Citations 5

Authors

Anna Lis-Swiety

Alina Skrzypek-Salamon

Irmina Ranosz-Janicka

Ligia Brzezinska-Wcislo

Affiliations

Soon will be listed here.

Abstract

Localized scleroderma (LoS) is a chronic fibrosing disorder of the skin and, less commonly, subcutaneous tissues. As the disease causes subjective symptoms, cosmetic defects, and, at times, functional disability, subjects with LoS experience deterioration of their health-related quality of life (HRQoL). The influence of disease activity/severity and damage status on HRQoL measures in patients with LoS is scarcely known. Physician-reported measures (modified LoS skin severity index, LoS skin damage index, physician global assessments of the disease activity/severity and damage) and patient-derived measures (patient global assessments of the disease activity/severity and damage) were obtained in adult LoS patients. Their HRQoL was measured with Skindex-29 and Short Form-36. The patients' assessments of disease activity/severity and damage in LoS differed from the assessments by the physicians. The patients' predominant concerns centered on LoS-related damage, whereas the physicians' concerns focused on features of disease activity. Visual analogue scales bore some relation to the HRQoL, and they seem to be important in a holistic approach to the patient and should not be omitted in LoS evaluation.

Citing Articles

Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms.

Wong L, Yen Y Diagnostics (Basel). 2022; 12(7).

PMID: 35885674 PMC: 9317505. DOI: 10.3390/diagnostics12071772.

Clinical and laboratory characterization of patients with localized scleroderma and response to UVA-1 phototherapy: In vivo and in vitro skin models.

Tognetti L, Marrocco C, Carraro A, Guerrini G, Mariotti G, Cinotti E Photodermatol Photoimmunol Photomed. 2022; 38(6):531-540.

PMID: 35324032 PMC: 9790552. DOI: 10.1111/phpp.12786.

UVA-1 phototherapy as adjuvant treatment for eosinophilic fasciitis: in vitro and in vivo functional characterization.

Tognetti L, Marrocco C, Carraro A, Conticini E, Habougit C, Mariotti G Int J Dermatol. 2021; 61(6):718-726.

PMID: 34881449 PMC: 9299925. DOI: 10.1111/ijd.16003.

A pilot study on ex vivo expanded autologous adipose-derived stem cells of improving fat retention in localized scleroderma patients.

Wang C, Long X, Si L, Chen B, Zhang Y, Sun T Stem Cells Transl Med. 2021; 10(8):1148-1156.

PMID: 33871949 PMC: 8284772. DOI: 10.1002/sctm.20-0419.

Lis-Swiety A, Skrzypek-Salamon A, Ranosz-Janicka I, Brzezinska-Wcislo L Health Qual Life Outcomes. 2020; 18(1):133.

PMID: 32398135 PMC: 7216592. DOI: 10.1186/s12955-020-01386-0.

References

Szramka-Pawlak B, Danczak-Pazdrowska A, Rzepa T, Szewczyk A, Sadowska-Przytocka A, Zaba R . Health-related quality of life, optimism, and coping strategies in persons suffering from localized scleroderma. Psychol Health Med. 2013; 18(6):654-63. DOI: 10.1080/13548506.2013.764461. View

Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J . Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005; 52(9):2873-81. DOI: 10.1002/art.21264. View

Skrzypek-Salamon A, Lis-Swiety A, Ranosz-Janicka I, Brzezinska-Wcislo L . Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study. Health Qual Life Outcomes. 2018; 16(1):185. PMC: 6137731. DOI: 10.1186/s12955-018-1010-z. View

Klimas N, Shedd A, Bernstein I, Jacobe H . Health-related quality of life in morphoea. Br J Dermatol. 2014; 172(5):1329-37. PMC: 4430379. DOI: 10.1111/bjd.13572. View

Das S, Bernstein I, Jacobe H . Correlates of self-reported quality of life in adults and children with morphea. J Am Acad Dermatol. 2014; 70(5):904-10. PMC: 3992170. DOI: 10.1016/j.jaad.2013.11.037. View

Bali G, Karpati S, Sardy M, Brodszky V, Hidvegi B, Rencz F . Association between quality of life and clinical characteristics in patients with morphea. Qual Life Res. 2018; 27(10):2525-2532. DOI: 10.1007/s11136-018-1897-1. View

Prinsen C, Lindeboom R, de Korte J . Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. J Invest Dermatol. 2011; 131(9):1945-7. DOI: 10.1038/jid.2011.138. View

Lis-Swiety A, Skrzypek-Salamon A, Ranosz-Janicka I, Brzezinska-Wcislo L . Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. J Eur Acad Dermatol Venereol. 2017; 31(10):1595-1603. DOI: 10.1111/jdv.14197. View

Lis-Swiety A, Janicka I, Skrzypek-Salamon A, Brzezinska-Wcislo L . A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. J Eur Acad Dermatol Venereol. 2016; 31(1):30-37. DOI: 10.1111/jdv.13790. View

10.

Arkachaisri T, Vilaiyuk S, Torok K, Medsger Jr T . Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford). 2009; 49(2):373-81. PMC: 3498950. DOI: 10.1093/rheumatology/kep361. View

11.

Kreuter A, Wischnewski J, Terras S, Altmeyer P, Stucker M, Gambichler T . Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol. 2012; 67(6):1157-62. DOI: 10.1016/j.jaad.2012.04.003. View

12.

Arkachaisri T, Vilaiyuk S, Li S, ONeil K, Pope E, Higgins G . The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009; 36(12):2819-29. PMC: 3690503. DOI: 10.3899/jrheum.081284. View

13.

Marzano A, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P . Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003; 13(2):171-6. View

14.

Ardalan K, Zigler C, Torok K . Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma. Arthritis Care Res (Hoboken). 2016; 69(7):1082-1087. PMC: 5376376. DOI: 10.1002/acr.23101. View

15.

Kroft E, de Jong E, Evers A . Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Arch Dermatol. 2008; 144(10):1394-5. DOI: 10.1001/archderm.144.10.1394. View

16.

Condie D, Grabell D, Jacobe H . Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort. Arthritis Rheumatol. 2014; 66(12):3496-504. PMC: 4245331. DOI: 10.1002/art.38853. View

17.

Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T . A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006; 54(3):440-7. DOI: 10.1016/j.jaad.2005.11.1063. View

18.

Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A . German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016; 14(2):199-216. DOI: 10.1111/ddg.12724. View